Aptose Biosciences Inc.

NasdaqCM:APTO Stock Report

Market Cap: US$13.0m

Aptose Biosciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

William Rice

Chief executive officer

US$924.7k

Total compensation

CEO salary percentage67.4%
CEO tenure11.3yrs
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure11.3yrs

Recent management updates

Recent updates

Aptose Biosciences Q2 2022 Earnings Preview

Aug 01

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Jul 19

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

Feb 02

Aptose: High Risk, High Reward. Watch Its Phase I Studies

Aug 05

Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow

Jun 18

Aptose Biosciences: An Assessment

Apr 27

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

Dec 08

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Nov 12

CEO Compensation Analysis

How has William Rice's remuneration changed compared to Aptose Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$925kUS$623k

-US$51m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$44m

Dec 31 2022US$2mUS$599k

-US$42m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

-US$58m

Mar 31 2022n/an/a

-US$61m

Dec 31 2021US$2mUS$582k

-US$65m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$12mUS$582k

-US$55m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$562k

-US$26m

Sep 30 2019n/an/a

-US$25m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$2mUS$540k

-US$29m

Compensation vs Market: William's total compensation ($USD924.67K) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: William's compensation has been consistent with company performance over the past year.

CEO

William Rice (65 yo)

11.3yrs

Tenure

US$924,668

Compensation

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

Leadership Team

NamePositionTenureCompensationOwnership
William Rice
Chairman11.3yrsUS$924.67kno data
Fletcher Payne
Senior VP2.6yrsUS$611.37k0.012%
$ 1.6k
Rafael Bejar
Senior VP & Chief Medical Officer5yrsUS$750.08k0.012%
$ 1.6k
Marc Wiles
Senior Vice President of Regulatory Affairs1.5yrsno datano data

3.8yrs

Average Tenure

61yo

Average Age

Experienced Management: APTO's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Rice
Chairman11.3yrsUS$924.67kno data
Mark Vincent
Independent Director17.3yrsUS$127.68k0.00073%
$ 94.9
Bernd Seizinger
Independent Director2.3yrsUS$132.17k0.031%
$ 4.0k
Denis Burger
Lead Independent Director17.3yrsUS$172.17k0.0024%
$ 315.8
Stephen Howell
Member of Scientific Advisory Boardno datano datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Erich Platzer
Independent Director10.1yrsUS$123.67k0.057%
$ 7.3k
Warren Whitehead
Independent Director13.8yrsUS$122.68k0.0017%
$ 218.3
Brian Druker
Chairman of Scientific Advisory Board11.3yrsno datano data
Michael Andreeff
Member of Scientific Advisory Board9.8yrsno datano data
Carol Ashe
Independent Director6.4yrsUS$123.67k0%
$ 0

11.3yrs

Average Tenure

71.5yo

Average Age

Experienced Board: APTO's board of directors are seasoned and experienced ( 11.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 02:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptose Biosciences Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Joseph PantginisH.C. Wainwright & Co.